Euglena soaring on Japanese stock exchange
May 20, 2013
Kengo Suzuki, head of Research and Development at Euglena Co., works in the company’s laboratory in Tokyo. Euglena, a venture formed by the University of Tokyo, has soared 10-fold this year for the second-best performance on the Tokyo Stock Exchange Mothers Index. Photographer: Tomohiro Ohsumi/Bloomberg
atoshi Kawano & Kanoko Matsuyama report for Bloomberg.com that a Japanese biotech venture focused on making jet fuel from algae is soaring in Tokyo trading as cash being pumped into the economy by the central bank cascades into speculative investments.
“The market expects quantitative and qualitative easing to continue long term, boosting liquidity and drawing investors to speculative shares like biotech,” said Kazuyuki Terao, chief investment officer at Allianz Global Investors Japan.
Euglena, a venture formed by the University of Tokyo, has soared 10-fold this year for the second-best performance on the Tokyo Stock Exchange Mothers Index. The company is developing single-cell algae based products including jet fuel, which it expects to supply steadily by 2018, its President, Mitsuru Izumo, said in an interview.
The venture is currently valued at about 157 billion yen (15.35 million USD) and trades at about 335 times forecast earnings. Still, Japan’s fastest-rising biotech companies have yet to produce steady profit, so the investors’ bets are speculative, said Terao of Allianz Global.
The JASDAQ index had an average price earnings ratio of about 22, based on analyst estimates for the year, while the Tokyo Stock Exchange Mother’s Index, which includes Euglena, averaged about 74 times earnings estimated by analysts, according to data compiled by Bloomberg.
The multiples for many of the companies aren’t prohibitively high, said Tomohiko Ikeno, an analyst at Ace Research Institute. “It is still a good time to invest in some Japanese biotech ventures to hold long term,” Ikeno said. “The stocks will be volatile in the short term, but still have great potential for gains.”
Copyright ©2010-2017 AlgaeIndustryMagazine.com. All rights reserved. Permission required to reprint this article in its entirety. Must include copyright statement and live hyperlinks. Contact firstname.lastname@example.org. A.I.M. accepts unsolicited manuscripts for consideration, and takes no responsibility for the validity of claims made in submitted editorial.
Visit our 2017 International Reader’s Poll Platinum Sponsors
From The A.I.M. Archives
— Refresh Page for More Choices
Algae.Tec has announced that, with the completion of the US$1M injection by Gencore, their nutraceutical plant upgrade in Cummings, Georgia, is progressing ahead of sched...
Stavanger, Norway-based Skretting, a 100+ year-old leader in the manufacture and supply of aquaculture feeds for fish and shrimp, has announced that they are now offering...
Jason Smith reports for undercurrentnews that Kentucky-based Alltech is willing to invest in overseas algae production plants closer to its feed customers if demand for i...
Cellana, Inc., a leading developer of algae-based products for sustainable nutrition and energy applications, and PIVEG, Inc., a leader in high-specification ingredients ...
Dan Wood, at the University of Connecticut, writes that assistant extension educator of marine aquaculture at UConn’s Avery Point Campus, Anoushka Concepcion, spoke about...
For algal biofuels to compete with petroleum, farming algae has to become less expensive. Toward that goal, Sandia National Laboratories is testing strains of algae for r...